GlassScriptPhysician profile
Anna Reznikova
NPI 1639474927
$8,324.91
in general payments reported to CMS, 2019-2025
27 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.65 · 2021: $1,283 · 2022: $1,524 · 2023: $1,302 · 2024: $2,312 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,174 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,174.13 |
| Education | $302.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,006.29 | 2021-2025 | |
| Janssen Biotech, INC. | $934.39 | 2021-2025 | Tremfya |
| Genzyme Corporation | $738.74 | 2021-2025 | |
| Leo Pharma INC. | $575.99 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $539.37 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $518.34 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $433.88 | 2021-2025 | |
| Incyte Corporation | $382.07 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $378.56 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Dermavant Sciences, INC. | $337.21 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $298.29 | 2022-2025 | Sotyktu |
| Amgen INC. | $278.08 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $257.64 | 2021-2025 | Bimzelx, Cimzia |
| Botanix Sb INC | $253.20 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $236.93 | 2021-2025 | Aklief, Nemluvio, Oracea |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $196.41 | 2019-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $173.92 | 2021-2025 | Arazlo, Jublia |
| Almirall LLC | $169.66 | 2021-2025 | Klisyri |
| Organon LLC | $153.28 | 2024-2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.82 | 2024-2025 | Spevigo |
| Paratek Pharmaceuticals, INC. | $94.42 | 2024-2025 | Nuzyra |
| Arcutis Biotherapeutics, INC. | $85.69 | 2024-2025 | Zoryve |
| Epi Health, LLC | $76.85 | 2021-2022 | |
| Lnhc, INC | $28.78 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $27.91 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $19.84 | 2021 | |
| Sebela Pharmaceuticals INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Reznikova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.